Evidence map›Paper›PMID 41326715›Full record

ArticleEMBO molecular medicine2026

Prediction of continuous amyloid positron emission tomography with fluid measures of phosphorylated tau and β-amyloid.

Niklas Mattsson-Carlgren, Linda Karlsson, Weizhong Tang, Kaj Blennow, Henrik Zetterberg, Randall J Bateman, Suzanne E Schindler, Nicolas Barthelemy, Sebastian Palmqvist, Erik Stomrud and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Niklas Mattsson-Carlgren *Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. Niklas.mattsson-carlgren@med.lu.se.ORCID http://orcid.org/0000-0002-8885-7724
Linda Karlsson *Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-0630-772X
Weizhong TangClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID http://orcid.org/0000-0002-1890-4193
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.ORCID http://orcid.org/0000-0003-3930-4354
Randall J BatemanDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.ORCID http://orcid.org/0000-0002-7729-1702
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Nicolas BarthelemyDepartment of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Sebastian PalmqvistClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.ORCID http://orcid.org/0000-0002-9267-1930
Erik StomrudClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Shorena JanelidzeClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.ORCID http://orcid.org/0000-0001-8467-7286

Funding

DIAN-TU: Tau Next Generation Prevention Trial - Administrative SupplementR01AG068319 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2020 to 2026
$81.4M
Blood amyloid, tau, and neurodegeneration biomarkers and prediction of clinical onset, cognitive decline, and dementia diagnosisR01AG061900 · NIA · WASHINGTON UNIVERSITY · PI RANDALL J BATEMAN · 2024 to 2026
$16.8M
Staging Alzheimer disease with blood-based biomarkersR01AG070941 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2021 to 2025
$4.3M
Alzheimer's Association (AA) ALZSI-26-1523522Alzheimer's Association (AA) ZEN24-1069572EC | European Research Council (ERC) ADG-101096455Knut and Alice Wallenberg Foundation 2022-0231Michael J Fox Foundation MJFF-025507NIA NIH HHS R01 AG061900NIA NIH HHS R01 AG068319NIA NIH HHS R01 AG070941Parkinson foundation of Sweden 1412/22Skåne University Hospital Foundation 2020-O000028Swedish Alzheimer Foundation AF-1011799Swedish Brain Foundation FO2025-0055Swedish federal government under the ALF agreement 2022-Projekt0107Swedish Research Council 2025-02319WASP and DDLS Joint call for research projects WASP/DDLS22-066
6 · The paper itself

Abstract

Brain amyloid-β (Aβ) pathology is a core feature of Alzheimer disease (AD) and can be quantified using positron emission tomography (PET). Cerebrospinal fluid (CSF) and plasma biomarkers detect abnormal Aβ, but it is unclear to what degree they can predict quantitative Aβ-PET. We explored plasma and CSF biomarkers in relation to Aβ-PET in the BioFINDER-2 study (N = 1053), and the BioFINDER-1 study (N = 238). We developed a machine learning pipeline to predict Aβ-PET using CSF and plasma measures. The best models achieved R

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesPositron-Emission Tomographytau ProteinsAgedAged, 80 and overBiomarkersBrainFemaleHumansMaleMiddle AgedPhosphorylationAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s DiseaseAmyloidClinical TrialsPETPlasma Biomarkers

Identifiers

PMID41326715
PMCPMC12808103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.